Novavax today announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy. The phase 3 trial, which enrolled more than 29,000 participants across the U.S. and Mexico, also demonstrated the vaccine to be safe. Additionally, the Novavax vaccine maintained a 93% efficacy against COVID-19 variants that emerged between January and April of this year.

The vaccine uses recombinant nanoparticle technology to generate a coronavirus spike protein-generated antigen. The company says the vaccine is stored and stable at 2-8 degrees Celsius (about 35-46 degrees Fahrenheit), enabling the use of existing vaccine supply chain channels for distribution.

Related News Articles

Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…